Impel Pharmaceuticals Inc. Common Stock
IMPL
IMPL was delisted on the 15th of December, 2023.
32 hedge funds and large institutions have $24.8M invested in Impel Pharmaceuticals Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 5 closing their positions.
0.96% less ownership
Funds ownership: 75.44% → 74.48% (-0.96%)
9% less funds holding
Funds holding: 35 → 32 (-3)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
75% less capital invested
Capital invested by funds: $99.6M → $24.8M (-$74.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DA
DCF Advisers
Greenwich,
Connecticut
|
+$137K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$71.6K |
| 3 |
Millennium Management
New York
|
+$70.2K |
| 4 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$34.4K |
| 5 |
JP Morgan Chase
New York
|
+$6.44K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$535K |
| 2 |
JGC
J. Goldman & Co
New York
|
-$286K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$187K |
| 4 |
Jane Street
New York
|
-$49.3K |
| 5 |
State Street
Boston,
Massachusetts
|
-$29.4K |
IMPL Hedge Fund Activity: Q1 2023 in Review
32 of the 6,284 institutional investors tracked by Wall St. Rank reported a position in Impel Pharmaceuticals Inc. Common Stock (IMPL) for Q1 2023, worth a combined $24.8M — down 75% from $99.6M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of IMPL and 3 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 6 added.
The largest buyer was DCF Advisers, adding an estimated $137K. The largest seller was Gilder Gagnon Howe & Co, exiting entirely with an estimated $535K sold.
- 32 institutional investors held Impel Pharmaceuticals Inc. Common Stock (IMPL) as of Q1 2023, down from 35 in Q4 2022.
- Funds reported $24.8M of Impel Pharmaceuticals Inc. Common Stock stock for Q1 2023, down 75% quarter-over-quarter.
- 3 funds opened new Impel Pharmaceuticals Inc. Common Stock positions in Q1 2023 and 5 closed out, a net change of -2 holders.
- The largest Impel Pharmaceuticals Inc. Common Stock buyer in Q1 2023 was DCF Advisers, an estimated $137K added.
- The largest Impel Pharmaceuticals Inc. Common Stock seller in Q1 2023 was Gilder Gagnon Howe & Co, an estimated $535K sold.
Based on aggregated 13F filings for Q1 2023.